Related Experiment Video
Updated: Apr 10, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
A Case of Pityriasis Lichenoides Chronica Successfully Treated With Upadacitinib
Olivia R Noble1, David J Cohen2, Lynn Cooper3
1Department of Medicine, Medical College of Georgia at Augusta University, Augusta, Georgia, USA, augusta.edu.
Abstract:
Pityriasis lichenoides chronica (PLC) is a chronic cutaneous disorder of unknown cause that is thought to be a proliferation of T-cells in response to an antigen or infection. We introduce a case of a 62-year-old female who presented with an erythematous nonpainful eruption of well-demarcated annular and polycyclic papules and plaques with fine whitish peripheral scale distributed on the back, shoulders, chest, arms, and legs. Skin biopsy was consistent with PLC. After minimal improvement with systemic and topical corticosteroids, oral upadacitinib 15 mg once daily was started. Following 1 month of treatment with oral upadacitinib, the complete remission of PLC was observed. Thus, upadacitinib as a Janus kinase (JAK) inhibitor may be a novel treatment for PLC. However, more studies are needed to explore the efficacy and safety of JAK inhibitors for lichenoid disorders, such as PLC and others.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
